This WHO guidelines recommend offering HIV testing and counselling to couples, wherever HIV testing and counselling is available, including in antenatal clinics. For couples where only one partner is HIV positive, the guidelines recommend offering antiretroviral therapy to the HIV positive partner, regar...
These recommendations have been developed specifically to address the daily use of antiretrovirals in HIV-uninfected people to block the acquisition of HIV infection. This prevention approach is known as pre-exposure prophylaxis. At this stage evidence is available from studies with two groups: men and t...
Adolescents (10–19 years) and young people (20–24 years) continue to be vulnerable, both socially and economically, to HIV infection despite efforts to date. This is particularly true for adolescents — especially girls — who live in settings with a generalized HIV epidemic or who are members of k...
This guideline provides an evidence-based recommendation on the use of adult male circumcision devices for HIV prevention in public health programmes in high HIV prevalence, resource-limited settings. It also presents key programmatic considerations for the introduction and use of these devices in public...
In this second supplement (December 2014) to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, recommendations from two guideline development processes are included: post-exposure prophylaxis for HIV; the use of co-trimoxazole prophylaxis for H...
During 9–12 March 2014, WHO convened a meeting of the Guideline Development Group (GDG) comprising 52 individuals representing a wide range of stakeholders, for the purpose of reviewing, and where appropriate, revising its Medical eligibility criteria for contraceptive use, fourth edition (MEC) guidanc...
Skin and mucosal conditions are extremely common in all children and adults in particular in HIV-infected adults and children and are one of the commonest daily management problems faced by health care workers caring for patients with HIV infection. As the CD4 count declines below 200 cells/mm3, the prev...
In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...
This early-release guideline makes available two key recommendations that were developed during the revision process in 2015. First, antiretroviral therapy (ART) should be initiated in everyone living with HIV at any CD4 cell count. Second, the use of daily oral pre-exposure prophylaxis (PrEP) is recomme...
The Consolidated guidelines on HIV testing services bring together existing guidance relevant to the provision of HIV testing services (HTS) and addresses issues and elements for effective delivery of HTS that are common in a variety of settings, contexts and diverse populations. In addition, this docume...
